Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders
28. Oktober 2019 16:01 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference
27. August 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
13. August 2019 16:05 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics to Present at the 2019 Webush PacGrow Healthcare Conference
01. August 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics to Host Conference Call and Webcast to Discuss Update on its Pipeline Programs
25. Juli 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Restructuring and Update on Pipeline Programs
05. Juli 2019 08:30 ET
|
Acer Therapeutics Inc.
Restructuring expected to extend cash runway through end of 2020 Acer plans to discuss EDSIVO™ CRL with FDA and will continue to advance additional pipeline products NEWTON, Mass., July 05, 2019 ...
Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients
25. Juni 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Poster Presentation at Society for Vascular Medicine Annual Meeting
31. Mai 2019 08:30 ET
|
Acer Therapeutics Inc.
Pilot study using claims database suggests that a minority of U.S. vEDS patients (34%) are being treated with antihypertensive medications Data show no significant difference in clinical event rates...
Acer Therapeutics to Present at Upcoming Investor Conferences
23. Mai 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., May 23, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...
Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
14. Mai 2019 16:01 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...